Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:38pm, Tuesday, 30'th Apr 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously ap
Why Sarepta (SRPT) Might Surprise This Earnings Season
10:31am, Tuesday, 30'th Apr 2024
Sarepta (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
08:30am, Wednesday, 24'th Apr 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasd
GSK Gears Up for Q1 Earnings: Here's What to Expect
02:21pm, Tuesday, 23'rd Apr 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
02:27am, Thursday, 11'th Apr 2024
Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial,
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
10:24am, Monday, 08'th Apr 2024
Sarepta Therapeutics will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has already taken a beating.
2 Biotech Stocks to Buy Hand Over Fist in April
08:45am, Saturday, 06'th Apr 2024
Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.
Outperforming ETF manager names a potential ‘50-bagger' in the stock market
07:10am, Saturday, 06'th Apr 2024
The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-ma
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 29'th Mar 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously ap
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 29'th Mar 2024
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
08:00am, Wednesday, 13'th Mar 2024
Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
05:45am, Friday, 08'th Mar 2024
Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid deman
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
09:47am, Monday, 04'th Mar 2024
Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
01:36pm, Thursday, 29'th Feb 2024
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
07:33pm, Wednesday, 28'th Feb 2024
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
